Filing Details
- Accession Number:
- 0000947871-24-000498
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-20 16:39:38
- Reporting Period:
- 2024-05-15
- Accepted Time:
- 2024-05-20 16:39:38
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1739174 | Biomx Inc. | PHGE | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1282930 | L Carl Gordon | C/O Orbimed Israel Gp Ltd. 5 Hahoshlim Street, Building B, 1St Fl. Herzliya Pituach L3 46686 | No | No | Yes | No | |
1569590 | Ltd. Gp Israel Orbimed | 5 Hahoshlim Street, Building B, 1St Fl. Herzliya Pituach L3 46686 | No | No | Yes | No | |
1569821 | Partnership Limited Gp Biofund Israel Orbimed | 5 Hahoshlim Street, Building B, 1St Fl. Herzliya Pituach L3 46686 | No | No | Yes | No | |
1706399 | Erez Chimovits | C/O Orbimed Israel Gp Ltd. 5 Hahoshlim Street, Building B, 1St Fl. Herzliya Pituach L3 46686 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-05-15 | 9,280,408 | $0.24 | 13,797,997 | No | 4 | X | Indirect | See footnotes |
Common Stock | Disposition | 2024-05-15 | 24,344 | $0.38 | 13,773,653 | No | 4 | S | Indirect | See footnotes |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | X | Indirect | See footnotes |
No | 4 | S | Indirect | See footnotes |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Warrants (Right to Buy) | Disposition | 2024-05-15 | 9,280,408 | $0.00 | 9,280,408 | $0.24 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2023-05-04 | 2033-05-04 | No | 4 | X | Indirect |
Footnotes
- On May 15, 2024, OrbiMed Israel Partners Limited Partnership ("OIP") exercised pre-funded warrants ("Warrants") to purchase 9,280,408 shares of the Issuer's common stock for $0.244 per share. OIP paid the exercise price on a cashless basis, resulting in the Issuer withholding 24,344 of the Warrant shares to pay the exercise price and issuing to OIP the remaining 9,256,064 shares. The shares of the Issuer's common stock withheld to pay the exercise price of the Warrants are matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), with a portion of OIP's purchase of certain derivative securities on March 15, 2024. OIP will disgorge to the Issuer the statutory "profits" pursuant to Section 16(b) of the Exchange Act that resulted from such transactions.
- These securities are held of record by OIP. OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits.
- Each of OrbiMed Israel, OrbiMed BioFund, Carl L. Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.